Back to Search
Start Over
HIV-associated lymphoma in the era of combination antiretroviral therapy: shifting the immunological landscape
- Source :
- Pathogens and Disease. 73:ftv044
- Publication Year :
- 2015
- Publisher :
- Oxford University Press (OUP), 2015.
-
Abstract
- HIV infection increases the risk of many types of cancer, including lymphoma. Combination antiretroviral therapy (cART) has reduced, but not eliminated, the risk of HIV-associated lymphoma. There has been a substantial shift in the subtypes of lymphoma observed in HIV-infected patients treated with cART. In this review, we will first outline these changes based on epidemiological studies and describe the impact of cART on lymphoma risk and mortality. Then, we will discuss some immunological factors that may contribute to the increased risk of lymphoma persisting after the administration of cART, including immunological non-response to therapy, chronic B-cell activation and dysfunction, T follicular helper cells, natural killer cells and altered lymphopoiesis. A better understanding of the pathophysiologic mechanisms of HIV-associated lymphoma under effective cART will inform future treatment strategies.
- Subjects :
- Microbiology (medical)
Cart
medicine.medical_specialty
Helper T lymphocyte
HIV Infections
virus
Biology
immune activation
Virus
lymphomagenesis
immune system diseases
Antiretroviral Therapy, Highly Active
hemic and lymphatic diseases
Epidemiology
medicine
Humans
Immunology and Allergy
Lymphopoiesis
antiretroviral drugs
Lymphoma, AIDS-Related
General Immunology and Microbiology
virus diseases
Cancer
General Medicine
chronic infection
medicine.disease
Lymphoma
Chronic infection
HIV-1
Infectious Diseases
Anti-Retroviral Agents
Immunology
Minireview
Subjects
Details
- ISSN :
- 2049632X
- Volume :
- 73
- Database :
- OpenAIRE
- Journal :
- Pathogens and Disease
- Accession number :
- edsair.doi.dedup.....034214260d05b590c6d1b2dcfa522a4a
- Full Text :
- https://doi.org/10.1093/femspd/ftv044